NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 185)
Posted On: 08/01/2018 5:59:15 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Encouraging Bioavailability Results from TurboCBD™ Study
Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning reported noteworthy bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. TurboCBD™ is a proprietary, DehydraTECH™ powered, cannabidiol (“CBD”) fortified hemp oil capsule developed by Lexaria. The study evaluated the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers. The study compared the 90 mg dose of Lexaria’s TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria’s DehydraTECH™ technology. Per the report, Lexaria’s TurboCBD™ capsules continued to deliver more CBD to blood than the positive control capsules at each subsequent time point in the study through to the 6-hour mark when the study was completed. These results validate earlier in vitro and in vivo studies that have assessed the company’s DehydraTECH™ technology. Further data is still being collected and analyzed from the study, including other pharmacokinetic study parameters such as metabolic data and the results of the cardiovascular and cognitive performance measures.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning reported noteworthy bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. TurboCBD™ is a proprietary, DehydraTECH™ powered, cannabidiol (“CBD”) fortified hemp oil capsule developed by Lexaria. The study evaluated the degree and speed of CBD absorption into blood plasma and potential cardiovascular and cognitive performance enhancement in 12 healthy male volunteers. The study compared the 90 mg dose of Lexaria’s TurboCBD™ to a 90 mg dose of a positive control formulation without Lexaria’s DehydraTECH™ technology. Per the report, Lexaria’s TurboCBD™ capsules continued to deliver more CBD to blood than the positive control capsules at each subsequent time point in the study through to the 6-hour mark when the study was completed. These results validate earlier in vitro and in vivo studies that have assessed the company’s DehydraTECH™ technology. Further data is still being collected and analyzed from the study, including other pharmacokinetic study parameters such as metabolic data and the results of the cardiovascular and cognitive performance measures.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼